Gerhard GrÃ¼nder

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9591073/publications.pdf

Version: 2024-02-01

201 papers	9,583 citations	50276 46 h-index	45317 90 g-index
229 all docs	229 docs citations	229 times ranked	9367 citing authors

#	Article	IF	Citations
1	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 2018, 51, 9-62.	3.3	787
2	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry, 2011, 44, 195-235.	3.3	774
3	Correlation Between Dopamine D2 Receptors in the Ventral Striatum and Central Processing of Alcohol Cues and Craving. American Journal of Psychiatry, 2004, 161, 1783-1789.	7.2	341
4	Anticipation of monetary and social reward differently activates mesolimbic brain structures in men and women. Social Cognitive and Affective Neuroscience, 2009, 4, 158-165.	3.0	336
5	Dissociation of neural networks for anticipation and consumption of monetary and social rewards. NeuroImage, 2010, 49, 3276-3285.	4.2	273
6	Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]Raclopride. Neuropsychopharmacology, 2002, 27, 248-259.	5.4	261
7	Correlation of Alcohol Craving With Striatal Dopamine Synthesis Capacity and D2/3Receptor Availability: A Combined [18F]DOPA and [18F]DMFP PET Study in Detoxified Alcoholic Patients. American Journal of Psychiatry, 2005, 162, 1515-1520.	7.2	253
8	Oxytocin Influences Processing of Socially Relevant Cues in the Ventral Tegmental Area of the Human Brain. Biological Psychiatry, 2013, 74, 172-179.	1.3	205
9	Mechanism of New Antipsychotic Medications. Archives of General Psychiatry, 2003, 60, 974.	12.3	200
10	Association of Low Striatal Dopamine D₂Receptor Availability With Nicotine Dependence Similar to That Seen With Other Drugs of Abuse. American Journal of Psychiatry, 2008, 165, 507-514.	7.2	189
11	Oxytocin plasma concentrations after single intranasal oxytocin administration â€“ A study in healthy men. Neuropeptides, 2012, 46, 211-215.	2.2	186
12	The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development. Neuropsychopharmacology, 2009, 34, 187-203.	5.4	161
13	The thalamus as the generator and modulator of EEG alpha rhythm: a combined PET/EEG study with lorazepam challenge in humans. NeuroImage, 2004, 22, 637-644.	4.2	160
14	Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nature Neuroscience, 2008, 11, 1381-1382.	14.8	150
15	Elevated [¹⁸F]Fluorodopamine Turnover in Brain of Patients with Schizophrenia: An [¹⁸F]Fluorodopa/Positron Emission Tomography Study. Journal of Neuroscience, 2007, 27, 8080-8087.	3.6	149
16	Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [¹⁸F]Fallypride PET Study. American Journal of Psychiatry, 2008, 165, 988-995.	7.2	139
17	The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nature Reviews Drug Discovery, 2009, 8, 197-202.	46.4	125
18	Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D 2 -like antagonist to a mixed D 1 -/D 2 -like antagonist. Psychopharmacology, 1998, 137, 223-232.	3.1	122

#	Article	IF	Citations
19	Impaired sleep quality and sleep duration in smokersâ€"results from the <scp>G</scp>erman <scp>M</scp>ulticenter <scp>S</scp>tudy on <scp>N</scp>icotine <scp>D</scp>ependence. Addiction Biology, 2014, 19, 486-496.	2.6	116
20	Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Molecular Psychiatry, 2008, 13, 606-613.	7.9	113
21	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	107
22	Subchronic Haloperidol Downregulates Dopamine Synthesis Capacity in the Brain of Schizophrenic Patients In Vivo. Neuropsychopharmacology, 2003, 28, 787-794.	5.4	105
23	Therapeutic Monitoring of New Antipsychotic Drugs. Therapeutic Drug Monitoring, 2004, 26, 156-160.	2.0	105
24	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World Journal of Biological Psychiatry, 2018, 19, 162-174.	2.6	103
25	A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of Psychiatric Research, 1996, 30, 441-451.	3.1	98
26	The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia. Neuropsychopharmacology, 2006, 31, 1027-1035.	5.4	96
27	Differential patterns of nucleus accumbens activation during anticipation of monetary and social reward in young and older adults. Social Cognitive and Affective Neuroscience, 2014, 9, 825-831.	3.0	92
28	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. Journal of Clinical Psychiatry, 2020, 81, .	2.2	86
29	Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. Frontiers in Psychiatry, 2020, 11, 5.	2.6	84
30	Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. NeuroImage, 2006, 30, 1332-1339.	4.2	71
31	â€˜Prefrontalâ€™ cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: An exploratory [18F]-fluoro-L-DOPA-PET investigation. Human Brain Mapping, 2007, 28, 931-939.	3.6	71
32	Neuroendocrine response to antipsychotics: effects of drug type and gender. Biological Psychiatry, 1999, 45, 89-97.	1.3	66
33	Asymmetry in dopamine D2/3 receptors of caudate nucleus is lost with age. NeuroImage, 2007, 34, 870-878.	4.2	65
34	Cariprazine, a new, orally active dopamine D_{2/3}receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Review of Neurotherapeutics, 2013, 13, 1141-1159.	2.8	63
35	Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. Journal of Nuclear Medicine, 2005, 46, 964-72.	5.0	61
36	Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6271-6276.	7.1	60

#	Article	IF	Citations
37	AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry, 2011, 44, 195-235.	3.3	59
38	Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Positron Emission Tomography. Neuropsychopharmacology, 1997, 17, 175-185.	5.4	56
39	Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry,the, 2016, 3, 717-729.	7.4	56
40	PET Studies of Net Bloodâ€"Brain Clearance of FDOPA to Human Brain: Age-Dependent Decline of [18F]Fluorodopamine Storage Capacity. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 807-819.	4.3	55
41	Bithalamical Deep Brain Stimulation in Tourette Syndrome Is Associated with Reduction in Dopaminergic Transmission. Biological Psychiatry, 2009, 66, e15-e17.	1.3	55
42	Acute Alcohol Effects on Neuronal and Attentional Processing: Striatal Reward System and Inhibitory Sensory Interactions under Acute Ethanol Challenge. Neuropsychopharmacology, 2004, 29, 1527-1537.	5.4	54
43	The Impact of Dopamine on Aggression: An [¹⁸F]-FDOPA PET Study in Healthy Males. Journal of Neuroscience, 2013, 33, 16889-16896.	3.6	51
44	High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. International Journal of Neuropsychopharmacology, 2004, 7, 421-430.	2.1	50
45	Opioid Receptor PET Reveals the Psychobiologic Correlates of Reward Processing. Journal of Nuclear Medicine, 2008, 49, 1257-1261.	5.0	48
46	Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging. Pharmacopsychiatry, 2011, 44, 236-248.	3.3	48
47	Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study. Neurobiology of Aging, 2010, 31, 447-463.	3.1	47
48	[18 F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1463-1470.	6.4	46
49	Striatal D2/D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study. Pharmacopsychiatry, 2008, 41, 169-175.	3.3	46
50	Serum concentrations of paliperidone versus risperidone and clinical effects. European Journal of Clinical Pharmacology, 2010, 66, 797-803.	1.9	43
51	Dopamine Autoreceptor Agonists in the Treatment of Schizophrenia and Major Depression*. Pharmacopsychiatry, 1992, 25, 254-260.	3.3	42
52	Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. European Neuropsychopharmacology, 2006, 16, 233-240.	0.7	40
53	In Vivo Evidence of Deep Brain Stimulation-Induced Dopaminergic Modulation in Tourette's Syndrome. Biological Psychiatry, 2012, 71, e11-e13.	1.3	40
54	Effects of Smoking Cessation on Presynaptic Dopamine Function of Addicted Male Smokers. Biological Psychiatry, 2016, 80, 198-206.	1.3	40

#	Article	IF	Citations
55	Striatal and Extrastriatal D2/D3-Receptor-Binding Properties of Ziprasidone. Journal of Clinical Psychopharmacology, 2008, 28, 608-617.	1.4	38
56	Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. Journal of Nuclear Medicine, 2003, 44, 109-16.	5.0	37
57	The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1958-1966.	4.3	35
58	Opiate-Induced Dopamine Release Is Modulated by Severity of Alcohol Dependence: An [18F]Fallypride Positron Emission Tomography Study. Biological Psychiatry, 2011, 70, 770-776.	1.3	34
59	Brain imaging research: Does the science serve clinical practice?. International Review of Psychiatry, 2007, 19, 541-558.	2.8	33
60	Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. International Journal of Neuropsychopharmacology, 2010, 13, 951-960.	2.1	33
61	Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. Neuroscience and Biobehavioral Reviews, 2019, 106, 141-164.	6.1	32
62	Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. Psychoneuroendocrinology, 2016, 73, 9-15.	2.7	31
63	Sertraline in pregnancy â€“ Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. Journal of Affective Disorders, 2017, 212, 1-6.	4.1	31
64	Increase in Serum Clomipramine Concentrations Caused by Valproate. Journal of Clinical Psychopharmacology, 2000, 20, 493-494.	1.4	31
65	Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharmacology, 1993, 111, 123-126.	3.1	30
66	Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels. Neuropsychobiology, 2002, 46, 33-40.	1.9	30
67	The P300 event-related potential and smoking â€" A population-based caseâ€“control study. International Journal of Psychophysiology, 2010, 77, 166-175.	1.0	30
68	Neural correlates of naturalistic social cognition: brain-behavior relationships in healthy adults. Social Cognitive and Affective Neuroscience, 2016, 11, 1741-1751.	3.0	30
69	Neural evidence for an association between social proficiency and sensitivity to social reward. Social Cognitive and Affective Neuroscience, 2014, 9, 661-670.	3.0	29
70	Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophrenia Research, 2019, 210, 143-148.	2.0	29
71	Disparate effects of first and second generation antipsychotics on cognition in schizophrenia â€“ Findings from the randomized NeSSy trial. European Neuropsychopharmacology, 2019, 29, 720-739.	0.7	29
72	Elevated [18F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease. NeuroImage, 2010, 49, 2933-2939.	4.2	28

#	Article	IF	Citations
73	Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. Journal of Clinical Psychopharmacology, 2016, 36, 554-561.	1.4	28
74	Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophrenia Bulletin, 2019, 45, 350-359.	4.3	28
75	In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D2-like dopamine receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 6819-6829.	3.0	27
76	Effects of antipsychotic treatment on cognition in healthy subjects. Journal of Psychopharmacology, 2013, 27, 374-385.	4.0	27
77	Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. NeuroImage, 2008, 40, 1222-1231.	4.2	26
78	Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. International Journal of Neuropsychopharmacology, 2013, 16, 745-754.	2.1	25
79	Pharmacokinetic patterns of risperidone-associated adverse drug reactions. European Journal of Clinical Pharmacology, 2016, 72, 1091-1098.	1.9	25
80	Effects of alexithymia and empathy on the neural processing of social and monetary rewards. Brain Structure and Function, 2017, 222, 2235-2250.	2.3	25
81	Subchronic Antidepressant Treatment with Venlafaxine or Imipramine and Effects on Blood Pressure and Heart Rate: Assessment by Automatic 24-Hour Monitoring. Pharmacopsychiatry, 1996, 29, 72-78.	3.3	24
82	Impact of Different Antidopaminergic Mechanisms on the Dopaminergic Control of Prolactin Secretion. Journal of Clinical Psychopharmacology, 2011, 31, 214-220.	1.4	24
83	P50 sensory gating and smoking in the general population. Addiction Biology, 2011, 16, 485-498.	2.6	24
84	Acute and Sustained Effects of Methylphenidate on Cognition and Presynaptic Dopamine Metabolism: An [¹⁸F]FDOPA PET Study. Journal of Neuroscience, 2014, 34, 14769-14776.	3.6	24
85	The German multiâ€centre study on smokingâ€related behaviorâ€”description of a populationâ€based caseâ€control study. Addiction Biology, 2011, 16, 638-653.	2.6	23
86	Neural activation during anticipation of opposite-sex and same-sex faces in heterosexual men and women. NeuroImage, 2013, 66, 223-231.	4.2	23
87	Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder. Behavioural Brain Research, 2021, 398, 113004.	2.2	23
88	Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. Therapeutic Drug Monitoring, 2021, 43, 79-102.	2.0	23
89	Pregnancy exposure to citalopram â€“ Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 213-219.	4.8	22
90	Pharmacokinetics of risperidone in different application forms â€“ Comparing long-acting injectable and oral formulations. European Neuropsychopharmacology, 2018, 28, 130-137.	0.7	22

#	Article	IF	Citations
91	Antidepressants in breast milk; comparative analysis of excretion ratios. Archives of Women's Mental Health, 2019, 22, 383-390.	2.6	22
92	Surrogate markers for cerebral blood flow correlate with [¹⁸F]â€fallypride binding potential at dopamine D_{2/3} receptors in human striatum. Synapse, 2013, 67, 199-203.	1.2	21
93	Effect of smoking on risperidone pharmacokinetics â€“ A multifactorial approach to better predict the influence on drug metabolism. Schizophrenia Research, 2017, 185, 51-57.	2.0	21
94	Is There an Advantage to Venlafaxine in Comparison with Other Antidepressants?. Human Psychopharmacology, 1997, 12, 53-64.	1.5	20
95	Serotonergic modulation of response inhibition and reâ€engagement? Results of a study in healthy human volunteers. Human Psychopharmacology, 2010, 25, 472-480.	1.5	20
96	Risperidone-induced extrapyramidal side effects. International Clinical Psychopharmacology, 2016, 31, 259-264.	1.7	20
97	Comparison of Clomethiazole and Diazepam in the Treatment of Alcohol Withdrawal Syndrome in Clinical Practice. European Addiction Research, 2017, 23, 211-218.	2.4	20
98	Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine. Clinical Pharmacokinetics, 2019, 58, 535-543.	3.5	20
99	Occupancy of striatal D 2 -like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psychopharmacology, 1999, 146, 81-86.	3.1	19
100	Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Research, 1999, 89, 275-280.	3.3	19
101	Anterior limbic alpha-like activity: a low resolution electromagnetic tomography study with lorazepam challenge. Clinical Neurophysiology, 2005, 116, 886-894.	1.5	19
102	Remission of Drug-Induced Hepatitis After Switching from Risperidone to Paliperidone. American Journal of Psychiatry, 2010, 167, 351-352.	7.2	19
103	Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients â€“ thinking of clinically relevant CYP2D6 interactions. Journal of Psychopharmacology, 2016, 30, 803-809.	4.0	19
104	Reduced serotonin transporter availability in patients with unipolar major depression reflect the level of anxiety. Molecular Psychiatry, 2008, 13, 557-557.	7.9	18
105	Reduced clearance of venlafaxine in a combined treatment with quetiapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 85, 116-121.	4.8	18
106	Editorial to Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology. Pharmacopsychiatry, 2018, 51, 5-6.	3.3	18
107	Human dopamine receptor D2/D3 availability predicts amygdala reactivity to unpleasant stimuli. Human Brain Mapping, 2010, 31, 716-726.	3.6	17
108	The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. European Psychiatry, 2009, 24, 143-148.	0.2	17

#	Article	IF	Citations
109	â€œAbsoluteâ€•or â€œrelativeâ€• Choosing the right outcome measure in neuroimaging. NeuroImage, 2009, 45, 258-259.	4.2	17
110	Functional Polymorphism in the Neuropeptide Y Gene Promoter (rs16147) Is Associated with Serum Leptin Levels and Waist-Hip Ratio in Women. Annals of Nutrition and Metabolism, 2013, 62, 271-276.	1.9	17
111	Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. Psychopharmacology, 2015, 232, 1607-1617.	3.1	17
112	Naming for Psychotropic Drugs: Dilemma and Challenge. Pharmacopsychiatry, 2017, 50, 1-2.	3.3	17
113	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) Tj ETQq1 1 0.784314 rgBT /Overlock Psychiatry, 2021, 22, 561-628.	2.6	17
114	Therapeutic Reference Ranges for Psychotropic Drugs: A Protocol for Systematic Reviews. Frontiers in Psychiatry, 2021, 12, 787043.	2.6	17
115	Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Current Opinion in Investigational Drugs, 2010, 11, 823-32.	2.3	17
116	Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. International Journal of Neuropsychopharmacology, 2007, 10, 149.	2.1	16
117	Genetic Variation in the Neuropeptide Y Gene Promoter Is Associated with Increased Risk of Tobacco Smoking. European Addiction Research, 2012, 18, 246-252.	2.4	16
118	The role of 5-HT in response inhibition and re-engagement. European Neuropsychopharmacology, 2013, 23, 830-841.	0.7	16
119	The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia. Psychopharmacology, 2018, 235, 2221-2232.	3.1	16
120	Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. Journal of Affective Disorders, 2018, 227, 506-511.	4.1	16
121	Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients. Journal of Clinical Psychiatry, 2018, 79, .	2.2	16
122	Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. Psychopharmacology, 2011, 218, 733-748.	3.1	15
123	Pregnancy exposure to quetiapine â€“ Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes. Schizophrenia Research, 2018, 195, 252-257.	2.0	15
124	Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. Clinical Pharmacokinetics, 2018, 57, 729-737.	3.5	14
125	Increased Turnover of Dopamine in Caudate Nucleus of Detoxified Alcoholic Patients. PLoS ONE, 2013, 8, e73903.	2.5	13
126	Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in MicroPET imaging studies. Neuropharmacology, 2014, 84, 152-158.	4.1	13

#	Article	IF	Citations
127	Clinical response in a risperidone-medicated naturalistic sample: patientsâ€™ characteristics and dose-dependent pharmacokinetic patterns. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 325-333.	3.2	13
128	Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. Journal of Psychopharmacology, 2021, 35, 273-278.	4.0	13
129	Tiagabine does not attenuate alcohol-induced activation of the human reward system. Psychopharmacology, 2007, 191, 975-983.	3.1	12
130	Impact of personal economic environment and personality factors on individual financial decision making. Frontiers in Psychology, 2014, 5, 158.	2.1	12
131	Measuring citalopram in blood and central nervous system. International Clinical Psychopharmacology, 2016, 31, 119-126.	1.7	12
132	Sex and body weight are major determinants of venlafaxine pharmacokinetics. International Clinical Psychopharmacology, 2018, 33, 322-329.	1.7	12
133	The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. Pharmacopsychiatry, 2021, 54, 191-199.	3.3	12
134	Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) â€“ Rationale and study design. , 2022, 1, 100104.		12
135	Dopamine D2/D3 receptor availability and venturesomeness. Psychiatry Research - Neuroimaging, 2011, 193, 80-84.	1.8	11
136	Cytochrome P450â€mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. British Journal of Clinical Pharmacology, 2017, 83, 1668-1675.	2.4	11
137	Enhancement of atomoxetine serum levels by co-administration of paroxetine. International Journal of Neuropsychopharmacology, 2008, 11, 289-91.	2.1	10
138	Suicide Attempt During Late Pregnancy With Quetiapine. Journal of Clinical Psychopharmacology, 2015, 35, 343-344.	1.4	10
139	Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone. Journal of Clinical Psychopharmacology, 2016, 36, 90-92.	1.4	10
140	Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia. Journal of Clinical Psychopharmacology, 2019, 39, 550-560.	1.4	10
141	Pregnancy exposure to venlafaxineâ€”Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. Journal of Affective Disorders, 2020, 266, 578-584.	4.1	10
142	Tranylcypromine Abuse Associated With Delirium and Thrombocytopenia. Journal of Clinical Psychopharmacology, 2000, 20, 270-271.	1.4	10
143	Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone. Journal of Clinical Psychiatry, 2019, 80, .	2.2	10
144	Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice. Frontiers in Psychiatry, 2022, 13, 832209.	2.6	10

#	Article	IF	Citations
145	Effects of psychotropic drugs on brain plasticity in humans. Restorative Neurology and Neuroscience, 2014, 32, 163-181.	0.7	9
146	Lamotrigine in pregnancy â€“ therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. International Clinical Psychopharmacology, 2015, 30, 249-254.	1.7	9
147	Distribution pattern of mirtazapine and normirtazapine in blood and CSF. Psychopharmacology, 2015, 232, 807-813.	3.1	9
148	Association of Common Polymorphisms in the Nicotinic Acetylcholine Receptor Alpha4 Subunit Gene with an Electrophysiological Endophenotype in a Large Population-Based Sample. PLoS ONE, 2016, 11, e0152984.	2.5	9
149	How to Treat Hypertension in Venlafaxine-Medicated Patientsâ€”Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. Journal of Clinical Psychopharmacology, 2018, 38, 498-501.	1.4	9
150	Duloxetine enters the brain â€“ But why is it not found in the cerebrospinal fluid. Journal of Affective Disorders, 2016, 189, 159-163.	4.1	8
151	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. European Journal of Clinical Pharmacology, 2019, 75, 1109-1116.	1.9	8
152	Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. International Clinical Psychopharmacology, 2019, 34, 241-246.	1.7	8
153	Pharmacokinetic interactions between clozapine and sertraline in smokers and nonâ€smokers. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 303-308.	2.5	8
154	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. Frontiers in Psychiatry, 2022, 13, 826138.	2.6	8
155	Lack of Association of a Functional Catechol-O-Methyltransferase Gene Polymorphism With Risk of Tobacco Smoking: Results From a Multicenter Case-Control Study. Nicotine and Tobacco Research, 2013, 15, 1322-1327.	2.6	7
156	Interaction Between Risperidone, Venlafaxine, and Metronidazole. Journal of Clinical Psychopharmacology, 2016, 36, 730-733.	1.4	7
157	Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 101-106.	4.8	7
158	Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system. Addiction Biology, 2017, 22, 1449-1458.	2.6	7
159	Prefrontal and striatal dopamine D2/D3 receptors correlate with fMRI BOLD activation during stopping. Brain Imaging and Behavior, 2022, 16, 186-198.	2.1	7
160	Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports, 2022, 9, 48-58.	3.4	7
161	The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients. Psychopharmacology, 1995, 117, 472-478.	3.1	6
162	Altered benzodiazepine receptor sensitivity in alcoholism: A study with fMRI and acute lorazepam challenge. Psychiatry Research - Neuroimaging, 2007, 154, 241-251.	1.8	6

#	Article	IF	Citations
163	Neuropsychological Correlates of Transcription Factor AP-2Beta, and Its Interaction with COMT and MAOA in Healthy Females. Neuropsychobiology, 2013, 68, 79-90.	1.9	6
164	Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study. Clinical Trials, 2016, 13, 251-259.	1.6	6
165	Replication of the association between CHRNA4 rs1044396 and harm avoidance in a large population-based sample. European Neuropsychopharmacology, 2016, 26, 150-155.	0.7	6
166	Psychedelics: A New Treatment Paradigm in Psychiatry?. Pharmacopsychiatry, 2021, 54, 149-150.	3.3	6
167	The negative impact of vitamin D on antipsychotic drug exposure may counteract its potential benefits in schizophrenia. British Journal of Clinical Pharmacology, 2022, 88, 3193-3200.	2.4	6
168	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. Lancet Psychiatry,the, 2022, 9, 291-306.	7.4	6
169	Pharmacokinetic correlates of venlafaxine: associated adverse reactions. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 851-857.	3.2	5
170	Peripheral Oxytocin Predicts Higher-Level Social Cognition in Men Regardless of Empathy Quotient. Pharmacopsychiatry, 2019, 52, 148-154.	3.3	5
171	Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample. Pharmacopsychiatry, 2021, 54, 31-35.	3.3	5
172	Serotonin and amyloid deposition: A link between depression and Alzheimerâ€™s disease?. Journal of Neurochemistry, 2021, 156, 560-562.	3.9	5
173	Prolactin secretion is not a core dimension of â€œatypicalityâ€• Psychopharmacology, 2002, 162, 93-93.	3.1	4
174	Clinically relevant changes in clozapine serum concentrations after breast reduction surgery. Australian and New Zealand Journal of Psychiatry, 2017, 51, 1059-1060.	2.3	4
175	Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1125-1138.	2.2	4
176	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 83-94.	3.2	4
177	Changes in Clozapine Bioavailability in a Percutaneous Endoscopic Gastrostomy-Fed Patient With Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology, 2020, 40, 306-308.	1.4	4
178	Treatment Goals for Patients with Schizophrenia â€" A Narrative Review of Physician and Patient Perspectives. Pharmacopsychiatry, 2021, 54, 53-59.	3.3	4
179	Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1437-1443.	3.2	4
180	The downside of downregulation. Brain, 2019, 142, 1500-1502.	7.6	3

#	Article	IF	Citations
181	Plasma Levels and Cerebrospinal Fluid Penetration of Venlafaxine in a Patient With a Nonfatal Overdose During a Suicide Attempt. Journal of Clinical Psychopharmacology, 2014, 34, 398-399.	1.4	2
182	The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism. Pharmacopsychiatry, 2020, 53, 65-70.	3.3	2
183	Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia. Psychiatric Quarterly, 2021, 92, 177-191.	2.1	2
184	Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate. Expert Review of Clinical Pharmacology, 2022, 15, 243-249.	3.1	2
185	BENZODIAZEPINE-RECEPTORS IN DEPRESSION AND ANXIETY MEASURED BY IOMAZENIL-SPECT. Clinical Neuropharmacology, 1992, 15, 201B.	0.7	1
186	Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. Clinical Pharmacokinetics, 2021, 60, 1583-1589.	3.5	1
187	Determination of Drug Concentrations in Serum and Dopamine Receptor Occupancy in Brain for Optimal Antipsychotic Drug Therapy. European Psychiatry, 2009, 24, .	0.2	0
188	Response from the authors. Clinical Trials, 2016, 13, 262-263.	1.6	0
189	Comprehensive measurements of intrauterine and postnatal exposure to lamotrigine. , 2018, 51, .		0
190	The effect of pharmacological interaction between a proton pump inhibitor pantoprazole and clozapine. Pharmacopsychiatry, 2018, 51, .	3.3	0
191	The clinical relevance of the pharmacological interaction between clozapine and sertraline. , 2019, 52, .		0
192	10 How valid are therapeutic reference ranges for psychotropic drugs?. , 2020, 53, .		0
193	P.0693 Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range. European Neuropsychopharmacology, 2021, 53, S507-S508.	0.7	0
194	P.0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) â€“ study design, rationale and current status. European Neuropsychopharmacology, 2021, 53, S306.	0.7	0
195	Therapeutic reference range for aripiprazole revised: A systematic review and combined analysis. Pharmacopsychiatry, 2022, , .	3.3	0
196	Ketamine Metabolite Plasma Levels as Potential Blood Markers of Ketamine Efficacy in Treatment Resistant Depression. Pharmacopsychiatry, 2022, , .	3.3	0
197	Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range. Pharmacopsychiatry, 2022, , .	3.3	0
198	How valid are therapeutic reference ranges for psychotropic drugs?. Pharmacopsychiatry, 2022, , .	3.3	0

#	Article	IF	Citations
199	The therapeutic reference range for olanzapine revised â€“ how to combine old and new findings. Pharmacopsychiatry, 2022, , .	3.3	0
200	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. Pharmacopsychiatry, 2022, , .	3.3	0
201	Case series: Higher antipsychotic drug levels in patients with schizophrenia after COVID-19 vaccination. Pharmacopsychiatry, 2022, , .	3.3	0